X. Le

发表

P2.04-90 Nodal Immune Flare (NIF) Following Neoadjuvant Anti-PD-1 and Anti-CTLA-4 Therapy in Non-Small Cell Lung Cancer

S. Swisher, J. Heymach, M. Godoy, 2019, Journal of Thoracic Oncology.

Evaluation of different chemical adjuvants on an avian influenza H6 DNA vaccine in chickens

T. Ellis, J. Edwards, X. Le, 2016, Avian pathology : journal of the W.V.P.A.

Development of a Nano-vaccine against a Wild Bird H6N2 Avian Influenza Virus

T. Ellis, J. Edwards, X. Le, 2010 .

LBA52 Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study

C. Dooms, F. de Marinis, J. Mazières, 2022, Annals of Oncology.

1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib

J. Riess, B. Cho, I. Okamoto, 2021, Annals of Oncology.

Clinical Case Report: Recurrence of CASTLE Thyroid Tumor

X. Le, V. Le, Thi Thu Nhung Nguyen, 2021 .

OA03.05 Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Primary Analysis of the Confirmatory VISION Cohort C

P. Paik, J. Mazières, Y. Wu, 2022, Journal of Thoracic Oncology.

EP08.02-162 Tepotinib with an EGFR-Tyrosine Kinase Inhibitor (TKI) in Patients with EGFR-mutant MET-amplified NSCLC: A Case Series

J. Mazières, L. Tho, X. Le, 2022, Journal of Thoracic Oncology.

P45.03 Tepotinib in Patients with MET exon 14 (METex14) Skipping NSCLC as Identified by Liquid (LBx) or Tissue (TBx) biopsy

P. Paik, E. Felip, C. Stroh, 2021, Journal of Thoracic Oncology.